DE69213010D1 - Verwendung eines Bakteriozin antibiotischen Agenten zur Herstellung eines Arzneimittels zur Behandlung von Magenverstimmungen, die durch Helicobacter pylori verursacht werden. - Google Patents

Verwendung eines Bakteriozin antibiotischen Agenten zur Herstellung eines Arzneimittels zur Behandlung von Magenverstimmungen, die durch Helicobacter pylori verursacht werden.

Info

Publication number
DE69213010D1
DE69213010D1 DE69213010T DE69213010T DE69213010D1 DE 69213010 D1 DE69213010 D1 DE 69213010D1 DE 69213010 T DE69213010 T DE 69213010T DE 69213010 T DE69213010 T DE 69213010T DE 69213010 D1 DE69213010 D1 DE 69213010D1
Authority
DE
Germany
Prior art keywords
treatment
bacteriocin
helicobacter pylori
pct
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69213010T
Other languages
English (en)
Other versions
DE69213010T2 (de
Inventor
Peter John Edwards
Kim Morwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Microbiology Inc
Original Assignee
Applied Microbiology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919108129A external-priority patent/GB9108129D0/en
Priority claimed from GB919114149A external-priority patent/GB9114149D0/en
Application filed by Applied Microbiology Inc filed Critical Applied Microbiology Inc
Publication of DE69213010D1 publication Critical patent/DE69213010D1/de
Application granted granted Critical
Publication of DE69213010T2 publication Critical patent/DE69213010T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
DE69213010T 1991-04-15 1992-04-10 Verwendung eines Bakteriozin antibiotischen Agenten zur Herstellung eines Arzneimittels zur Behandlung von Magenverstimmungen, die durch Helicobacter pylori verursacht werden. Expired - Fee Related DE69213010T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919108129A GB9108129D0 (en) 1991-04-15 1991-04-15 Pharmaceutical composition
GB919114149A GB9114149D0 (en) 1991-07-01 1991-07-01 Pharmaceutical composition
PCT/GB1992/000656 WO1992018143A1 (en) 1991-04-15 1992-04-10 Pharmaceutical compositions against gastric disorders

Publications (2)

Publication Number Publication Date
DE69213010D1 true DE69213010D1 (de) 1996-09-26
DE69213010T2 DE69213010T2 (de) 1997-01-23

Family

ID=26298737

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69213010T Expired - Fee Related DE69213010T2 (de) 1991-04-15 1992-04-10 Verwendung eines Bakteriozin antibiotischen Agenten zur Herstellung eines Arzneimittels zur Behandlung von Magenverstimmungen, die durch Helicobacter pylori verursacht werden.

Country Status (10)

Country Link
US (1) US5559096A (de)
EP (1) EP0589893B1 (de)
JP (1) JP3334879B2 (de)
AT (1) ATE141511T1 (de)
AU (1) AU665188B2 (de)
CA (1) CA2108455C (de)
DE (1) DE69213010T2 (de)
DK (1) DK0589893T3 (de)
IE (1) IE921193A1 (de)
WO (1) WO1992018143A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4139883A1 (de) * 1991-11-29 1993-06-03 Michael Prof Dr Dittgen Verfahren zur herstellung bioadhaesiver arzneimittel
EP0661988A1 (de) * 1991-12-09 1995-07-12 Magainin Pharmaceuticals Inc. Zusammensetzung aus und behandlung mit biologisch aktiven peptiden und chelatbildern
AU5174593A (en) * 1992-10-29 1994-05-24 Rainer Denecke Preparation for therapeutic and especially prophylactic treatment of digestive tract disorders
DE4307352A1 (de) * 1992-10-29 1994-05-05 Denecke Rainer Dr Med Vet Präparat zur Therapie und insbesondere Prophylaxe von Erkrankungen des Verdauungstraktes
US5512269A (en) * 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
US6077822A (en) * 1993-09-14 2000-06-20 Dumex-Alpharma A/S Drug salts
US6521596B1 (en) * 1994-04-20 2003-02-18 The Uab Research Foundation Lanthionine antibiotic compositions and method
US6902738B2 (en) * 1994-05-02 2005-06-07 Josman Laboratories, Inc. Topical oral dosage forms containing bismuth compounds
US5834002A (en) 1994-05-02 1998-11-10 Josman Laboratories, Inc. Chewing gum containing colloidal bismuth subcitrate
US6426085B1 (en) 1994-05-02 2002-07-30 Josman Laboratories Inc. Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis
JPH08133971A (ja) * 1994-09-16 1996-05-28 Toyama Chem Co Ltd 抗ヘリコバクター剤
US6379651B1 (en) * 1995-02-07 2002-04-30 Josman Laboratories Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases
US6372784B1 (en) 1995-02-07 2002-04-16 Josman Laboratories, Inc. Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds
US5804549A (en) * 1996-01-05 1998-09-08 Ambi Inc. Compositions with activity against helicobacter
GB9710699D0 (en) 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
US5972933A (en) * 1998-01-08 1999-10-26 Ed. Geistlich Sohne Ag Fur Chemische Industrie Method of treating microbial infections
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US20020004502A1 (en) 2000-01-05 2002-01-10 Redmond H. Paul Treatment of inflammatory bowel disease
KR100375342B1 (ko) * 2000-02-08 2003-03-08 주식회사 풀 무 원 위장 질환 개선을 위한 천연 항균물질 조성물
EP1148064A1 (de) * 2000-04-17 2001-10-24 Vrije Universiteit Brussel Ein aus Lactobacillus johnsonii faecium stammendes gegen Helicobacter pylori wirksames bakteriocin
US6342385B1 (en) 2000-07-28 2002-01-29 The Uab Research Foundation Mutacin I biosynthesis genes and proteins
DE60105452T2 (de) * 2001-05-03 2005-10-13 Farmigea S.P.A. Sucralfat enthaltendes arzneimittel zur behandlung von zervikale erosion
GB0217056D0 (en) * 2002-07-23 2002-08-28 Ass Octel Use
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
WO2005065317A2 (en) * 2003-12-31 2005-07-21 Cima Labs Inc. Effervescent oral fentanyl dosage form
ATE498395T1 (de) * 2003-12-31 2011-03-15 Cima Labs Inc Allgemein lineare brauseform von fentanyl zur oralen anwendung und verfahren zur verabreichung
CA2549642C (en) * 2003-12-31 2012-10-30 Cima Labs Inc. Effervescent oral opiate dosage forms and methods of administering opiates
AR073014A1 (es) 2008-08-12 2010-10-06 Dsm Ip Assets Bv Composiciones liquidas de nisina
CA2738114A1 (en) 2008-09-22 2010-04-08 Rubicon Research Private Limited Compositions exhibiting delayed transit through the gastrointestinal tract
AR080194A1 (es) 2010-02-17 2012-03-21 Dsm Ip Assets Bv Composiciones antimicrobianas liquidas
US9200251B1 (en) 2011-03-31 2015-12-01 David Gordon Bermudes Bacterial methionine analogue and methionine synthesis inhibitor anticancer, antiinfective and coronary heart disease protective microcins and methods of treatment therewith

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985002092A1 (en) * 1983-11-14 1985-05-23 Bio-Mimetics Inc. Bioadhesive compositions and methods of treatment therewith
US5334582A (en) * 1988-06-22 1994-08-02 Applied Microbiology, Inc. Pharmaceutical bacteriocin compositions and methods for using the same
US5304540A (en) * 1988-06-22 1994-04-19 Applied Microbiology, Inc. Pharmaceutical bacteriocin compositions and methods for using the same
US4980163A (en) * 1989-03-01 1990-12-25 Public Health Research Institute Of The City Of New York Novel bacteriocin compositions for use as enhanced broad range bactericides and methods of preventing and treating microbial infection

Also Published As

Publication number Publication date
IE921193A1 (en) 1992-10-21
JPH07503451A (ja) 1995-04-13
EP0589893B1 (de) 1996-08-21
US5559096A (en) 1996-09-24
EP0589893A1 (de) 1994-04-06
ATE141511T1 (de) 1996-09-15
CA2108455A1 (en) 1992-10-16
JP3334879B2 (ja) 2002-10-15
CA2108455C (en) 1999-01-19
DK0589893T3 (da) 1996-09-09
AU665188B2 (en) 1995-12-21
AU1581192A (en) 1992-11-17
DE69213010T2 (de) 1997-01-23
WO1992018143A1 (en) 1992-10-29

Similar Documents

Publication Publication Date Title
DE69213010T2 (de) Verwendung eines Bakteriozin antibiotischen Agenten zur Herstellung eines Arzneimittels zur Behandlung von Magenverstimmungen, die durch Helicobacter pylori verursacht werden.
NO960067D0 (no) Nytt farmasöytisk preparat
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
DE69533112T2 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
EP0509317A3 (en) Use of droloxifene in the treatment of bone diseases
NL990012I1 (nl) Geneesmiddelen die salmeterol en fluticason bevatten.
DK0733046T3 (da) Benzoylguanidiner, deres fremstilling og anvendelse i medikamenter
DE69400799D1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
WO1992018111A3 (en) Pharmaceutical composition for the treatment of gastritis
CA2429793A1 (en) Interferon therapeutic effect enhancer
DE69230790T2 (de) Arzneimittel zur Behandlung von durch Babesia verursachten Protozoeninfektionen
ATE28566T1 (de) Zellgiftiges arzneimittel enthaltend mindestens ein immunotoxin und ein amin.
HK1011527A1 (en) Use of allylamine derivatives such as terbinafine, in the manufacture of a medicament for the treatment of helicobacter pylori infection of associated diseases
GB9216859D0 (en) Medicaments
GB8921516D0 (en) Medicaments
ATE107504T1 (de) Arzneimittel zur behandlung von kryptosporidiose.
CZ176395A3 (en) The use of riluzol for preparing medicaments acceptable as antidotes against harmful effects of irradiation

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee